RECRUITING

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are: * Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function? Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.

Official Title

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Quick Facts

Study Start:2023-01-01
Study Completion:2029-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05593549

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Clinical Diagnosis of Type 2 Diabetes Mellitus in accordance with American Diabetes Association (ADA) guidelines (Type 2 Diabetic group)
  2. * Otherwise healthy individuals (Healthy control group) with no more than 1 cardiovascular risk factor
  1. * Uncontrolled hypertension
  2. * Current Tobacco use or within last 6 months
  3. * BMI \> 35
  4. * Hyperlipidemia
  5. * Hypercholesterolemia
  6. * Type 1 Diabetes
  7. * Use of anti-coagulant drugs, or anti-platelet drugs
  8. * Symptomatic coronary artery disease
  9. * Heart Failure
  10. * Renal Impairment
  11. * Hormone Replacement Therapy
  12. * History of Retinopathy
  13. * Documented Neuromuscular Disorders
  14. * Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
  15. * Pregnancy (Young Female subjects)
  16. * Allergies to Povidone Iodine
  17. * Use Erectile Dysfunction Medication in the past 6 months
  18. * Use of Topical/non-topical Steroids in last 6 months
  19. * Active Anti-Cancer Treatment or Treatment within last 12 months
  20. * Active COVID-19 or within the past 3 months
  21. * Gender Reassignment Therapy

Contacts and Locations

Study Contact

William Hughes, Ph.D.
CONTACT
414-955-7519
whughes@mcw.edu

Principal Investigator

William Hughes, Ph.D.
PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin

Study Locations (Sites)

Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Medical College of Wisconsin

  • William Hughes, Ph.D., PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-01
Study Completion Date2029-12-31

Study Record Updates

Study Start Date2023-01-01
Study Completion Date2029-12-31

Terms related to this study

Keywords Provided by Researchers

  • autophagy
  • microvascular function
  • laser doppler microdialysis

Additional Relevant MeSH Terms

  • Type 2 Diabetes
  • Healthy Aging